John Solak, derivatively on behalf of Ultragenyx Pharmaceutical Inc. v. Daniel G. Welch

CourtCourt of Chancery of Delaware
DecidedOctober 30, 2019
DocketC.A. No. 2018-0810-KSJM
StatusPublished

This text of John Solak, derivatively on behalf of Ultragenyx Pharmaceutical Inc. v. Daniel G. Welch (John Solak, derivatively on behalf of Ultragenyx Pharmaceutical Inc. v. Daniel G. Welch) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
John Solak, derivatively on behalf of Ultragenyx Pharmaceutical Inc. v. Daniel G. Welch, (Del. Ct. App. 2019).

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

JOHN SOLAK, derivatively on behalf ) of ULTRAGENYX ) PHARMACEUTICAL INC., ) ) Plaintiff, ) ) v. ) C.A. No. 2018-0810-KSJM ) DANIEL G. WELCH, EMIL D. ) KAKKIS, M.D., Ph.D., WILLIAM ) ALISKI, DEBORAH DUNSIRE, M.D., ) LARS EKMAN, M.D., Ph.D., ) MATTHEW K. FUST, MICHAEL ) NARACHI and CLAY B. SIEGALL, ) Ph.D., ) ) Defendants, ) ) and ) ) ULTRAGENYX ) PHARMACEUTICAL INC., a ) Delaware corporation, ) ) Nominal Defendant. )

MEMORANDUM OPINION Date Submitted: August 1, 2019 Date Decided: October 30, 2019

Blake A. Bennett, COOCH AND TAYLOR, P.A., Wilmington, Delaware; Jeffrey M. Norton, NEWMAN FERRARA LLP, New York, New York; Werner R. Kranenburg, KRANENBURG, London, United Kingdom; Counsel for Plaintiff John Solak.

Edward B. Micheletti, Lilianna Anh P. Townsend, Mary T. Reale, SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP, Wilmington, Delaware; Counsel for Defendants Ultragenyx Pharmaceutical Inc., Daniel G. Welch, Emil D. Kakkis, William Aliski, Deborah Dunsire, Lars Ekman, Matthew K. Fust, Michael Narachi, and Clay B. Siegall.

McCORMICK, V.C. As interpreted by the Delaware Supreme Court in Spiegel v. Buntrock,1 Court

of Chancery Rule 23.1 gives a stockholder wishing to file a derivative lawsuit two

mutually exclusive options. The stockholder may either make a pre-suit demand on

the board or plead with particularity the reasons it would have been futile to do so.

If a stockholder elects to make a pre-suit demand, then the stockholder may not

allege that demand would have been futile in a subsequent complaint concerning the

subject matter of the demand. Rather, the stockholder is limited to making the more

difficult claim that the board wrongfully refused the demand. Making a pre-suit

demand, therefore, carries significant downsides affecting the viability of a

derivative claim.

The parties in this case dispute whether a pre-suit communication constitutes

a pre-suit demand for purposes of Rule 23.1. Before commencing this litigation, the

plaintiff-stockholder sent a letter requesting that the defendant-company’s board of

directors take remedial action to address allegedly excessive non-employee director

compensation. This lawsuit ensued after the board rejected the letter’s request. The

plaintiff portrays the letter as no more than an informal, good faith attempt to educate

the board and encourage it to make changes to the company’s compensation policies.

He argues that demand futility is the appropriate standard and that the complaint

demonstrates that demand is excused. The defendants have moved to dismiss the

1 571 A.2d 767, 772–73 (Del. 1990).

1 complaint under Rule 23.1. They argue that the letter constitutes a pre-suit demand

and that the plaintiff failed to plead wrongful demand refusal.

Revealing the proverbial wolf in sheep’s clothing, this decision finds that what

the plaintiff describes as a harmless letter seeking prospective board action is

something with far more legal bite—a pre-suit demand. Because the plaintiff fails

to allege wrongful demand refusal, the action is dismissed.

I. FACTUAL BACKGROUND The facts are drawn from the Complaint, 2 documents it incorporates by

reference, and relevant pre-suit communications.3

Plaintiff John Solak (“Plaintiff”) is a current stockholder of Ultragenyx

Pharmaceutical Inc. (“Ultragenyx” or the “Company”), a biopharmaceutical

company incorporated under Delaware law and headquartered in Novato, California.

In June 2018, Plaintiff’s counsel sent a letter on his behalf (the “Letter”) addressed

to the Ultragenyx Board of Directors (the “Board”).4

2 C.A. No. 2018-0810-KSJM, Docket (“Dkt.”) 1, Verified Shareholder Derivative Compl. for Breach of Fiduciary Duty, Unjust Enrichment, and Waste of Corporate Assets (“Compl.”). 3 City of Tamarac Firefighters’ Pension Tr. Fund v. Corvi, 2019 WL 549938, at *2 & n.3 (Del. Ch. Feb. 12, 2019) (citing authorities for the proposition that the Court may consider pre-suit communications for Rule 23.1 purposes); see, e.g., Yaw v. Talley, 1994 WL 89019, at *7–8 (Del. Ch. Mar. 2, 1994) (considering pre-suit communications). 4 See Dkt. 18, Transmittal Aff. of Blake A. Bennett Ex. A (“Letter”).

2 The Letter states that its purpose is “to suggest that the [Board] take corrective

action to address excessive director compensation as well as compensation practices

and policies pertaining to directors.”5 The Letter focuses on the Company’s updated

compensation policy disclosed in its Definitive Proxy Statement filed with the

United States Securities and Exchange Commission on April 27, 2018 (the

“Compensation Policy”), which “the Board approved” and in which all non-

employee directors participate.6

According to the Letter, non-employee directors have been “compensated at

an extraordinarily high level – averaging in excess of $400,000 per annum each since

2014” under the Compensation Policy. 7 The Letter compares the median

compensation for non-employee directors at the “Top 200” companies in the

S&P 500 against the median total compensation for non-employee directors at

Ultragenyx, describing the latter as comparatively excessive.8

5 Id. at 1. 6 Id. (“Under the Compensation Policy, the compensation of each non-employee director consists of: (i) a $50,000 annual cash retainer; (ii) an annual option grant to purchase up to 3,750 shares of the Company’s common stock; and (iii) an annual grant of 1,875 restricted stock units. Additionally, non-employee directors acting as Chair of the Board or of certain Board committees are eligible for additional fees of up to $30,000 per director and other members of committees receive fees of up to $10,000 per committee. In addition, newly appointed non-employee directors will receive an option grant to purchase up to 15,000 shares of the Company’s common stock.”). 7 Id. 8 Id. at 2.

3 The Letter references In re Investors Bancorp, Inc. Stockholder Litigation, in

which the Delaware Supreme Court revived claims challenging director

compensation decisions a board made pursuant to a stockholder-approved,

discretionary equity incentive plan.9 In reversing the Court of Chancery decision

dismissing those claims, the Delaware Supreme Court held: “[W]hen it comes to the

discretion directors exercise following stockholder approval of an equity incentive

plan, ratification cannot be used to foreclose the Court of Chancery from reviewing

those further discretionary actions when a breach of fiduciary duty claim has been

properly alleged.”10 Citing Investors Bancorp, the Letter states: “The Compensation

Policy lacks any meaningful limitations with regard to cash and equity awards,

allows for too much discretion by the Board, and . . . is not subject to shareholder

approval.”11 The Letter then warns: “The Company is more susceptible than ever to

shareholder challenges unless it revises or amends its director compensation

practices and policies.” 12

The Letter concludes by “suggesting” that the Board “take[] immediate

remedial measures to address these issues, including, but not limited to, reducing

retainer fees, reducing the awards of options and restricted stock units, moving to

9 177 A.3d 1208 (Del. 2017). 10 Id. at 1222. 11 Letter at 2. 12 Id.

4 full-value equity grants, adopting mandatory stock-ownership guidelines, and

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Spiegel v. Buntrock
571 A.2d 767 (Supreme Court of Delaware, 1990)
Pogostin v. Rice
480 A.2d 619 (Supreme Court of Delaware, 1984)
Grimes v. Donald
673 A.2d 1207 (Supreme Court of Delaware, 1996)
Stotland v. GAF Corp.
469 A.2d 421 (Supreme Court of Delaware, 1983)
Zapata Corp. v. Maldonado
430 A.2d 779 (Supreme Court of Delaware, 1981)
Aronson v. Lewis
473 A.2d 805 (Supreme Court of Delaware, 1984)
Espinoza v. Dimon
124 A.3d 33 (Supreme Court of Delaware, 2015)
In Re Investors Bancorp, Inc. Stockholder Litigation
177 A.3d 1208 (Supreme Court of Delaware, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
John Solak, derivatively on behalf of Ultragenyx Pharmaceutical Inc. v. Daniel G. Welch, Counsel Stack Legal Research, https://law.counselstack.com/opinion/john-solak-derivatively-on-behalf-of-ultragenyx-pharmaceutical-inc-v-delch-2019.